Diabetes, Lipids, and CV Risk
Author:
- 19 January 2021
- journal article
- review article
- Published by Springer Nature in Current Atherosclerosis Reports
- Vol. 23 (3) , 1-6
Abstract
Purpose of Review Diabetes is often associated with diabetic dyslipidemia. Both hyperglycemia and disorders of lipid metabolism strongly contribute to development of atherosclerosis, the crucial factor of cardiovascular disease. The aim of the manuscript is to summarize possible treatment to reduce cardiovascular risk. Recent Findings Maximal cardiovascular risk reduction is maintained by targeting more pathologic disturbances together. While antihypertensive treatment has not changed much recently, novel PCSK9 inhibitors have significantly improved management of dyslipidemia. Similarly, modern antihyperglycemic agents (SGLT2 inhibitors and GLP-1 receptor agonists) show both significant metabolic effects and cardiovascular benefits. Summary Diabetes treatment is no longer glucocentric. Apart from glucose management, there are effective pharmacologic tools for significant reduction of cardiovascular risk.Keywords
This publication has 44 references indexed in Scilit:
- Association of Lower Extremity Arterial Calcification with Amputation and Mortality in Patients with Symptomatic Peripheral Artery DiseasePLOS ONE, 2014
- Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part IEuropean Heart Journal, 2013
- The emerging challenge in diabetes: The “metabolic memory”Vascular Pharmacology, 2012
- Bariatric Surgery and Long-term Cardiovascular EventsJAMA, 2012
- Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin TherapyNew England Journal of Medicine, 2011
- Receptor for AGE (RAGE) and its ligands—cast into leading roles in diabetes and the inflammatory responseJournal of Molecular Medicine, 2009
- 10-Year Follow-up of Intensive Glucose Control in Type 2 DiabetesNew England Journal of Medicine, 2008
- Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysisThe Lancet, 2008
- Atherosclerosis in diabetes and insulin resistanceDiabetes, Obesity and Metabolism, 2006
- Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialThe Lancet, 2005